Abstract: The unmet need for specific anti-leukemic agents for the treatment of acute lymphoblastic leukemia led us to screen a variety of marine-derived bacteria. The fermentation broth extract of *Streptomyces* sp. LY1209 exhibited the most potent anti-proliferative effect against Molt 4 leukemia cells. A chromatographic anti-proliferative profiling approach was applied to characterize the metabolites with bioactive potential. Among all the metabolites, the major anti-leukemic constituents were staurosporine and a series of diketopiperazines (DKPs), including one novel and two known DKPs identified from nature for the first time. The structures of these compounds were identified using extensive spectroscopic analysis. The anti-proliferative potential of these metabolites against Molt 4 was determined. According to the in silico analysis utilizing a chemical global positioning system for natural products (ChemGPS-NP), it was suggested that these DKPs are potential anti-microtubule and alkylating agents, while staurosporine was proposed to be a tyrosine kinase inhibitor. Our findings not only identified a series of anti-proliferative metabolites, but also suggested a strategic workflow for the future discovery of natural product drug leads.

Keywords: *Streptomyces* sp. LY1209; chromatographic bioassay profile; staurosporine; diketopiperazines

1. Introduction

Acute lymphocytic leukemia (ALL) is invasive leukemia characterized by the proliferation of lymphoblasts or lymphocytes in the bone marrow and peripheral blood. These
immature leukemic cells can spread to the lymph nodes, spleen, liver, central nervous system, and other organs. They can displace normal red blood cells [1]. ALL progresses quickly if not treated, and it causes thousands of deaths annually in the United States, according to the American Cancer Society. ALL patients are usually treated with a combination of unspecific conventional chemotherapeutic agents such as vincristine, imatinib, etoposide, methotrexate, and cytarabine [2]. Despite the diversity of the drugs used, serious side effects are the most common drawbacks of these chemotherapeutic regimens. In addition, the use of common cytotoxic drugs for ALL urges the scientific community to search for more specific agents [3,4]. The Molt 4 cell line is the most sensitive T-cell ALL cell line, and can be used to search for potential novel anti-leukemic agents.

Streptomyces sp. bacteria have drawn scientists’ attention for several decades since the discovery of the first antibiotic, streptomycin, from Streptomyces griseus in 1943 [5]. The subsequent chemical and pharmacological investigation of Streptomyces sp. led to the discovery of several clinical chemotherapeutic agents, such as dactinomycin, doxorubicin, daunorubicin, and anthracyclines. Insight into these interesting secondary metabolites, diketopiperazines (DKPs, also called dipeptides, dipeptide anhydrides, or 2,5-dioxopiperazines), a group of compounds identified from Streptomyces sp., drew much attention due to their well-known activity as antibacterial, anti-proliferative, anti-hepatoma, and anti-fungal agents [6,7]. A highly oxidized DKP, bicyclomycin, was identified from Streptomyces cinnamoneus and was approved as an antibiotic with an unusual mechanism of action [8]. Several recent studies have focused on discovering the cytotoxic potential of these DKPs [9–14], but relatively few research efforts have addressed their anti-leukemic properties [15]. The rich chemical diversity and potent cytotoxic potential of Streptomyces sp. motivated us to screen a series of marine-derived strains of this genus. In the current study, we aimed to illustrate the anti-proliferative potential of our identified strain, Streptomyces sp. LY1209, and to further examine its major bioindicators based on a chromatographic anti-proliferative profiling approach. Moreover, a computational tool based on the principal component analysis (PCA) of physical–chemical properties, ChemGPS-NP, was applied to interpret the possible mode of its anti-proliferative activity.

2. Results and Discussion

2.1. Establishment of High-Performance Liquid Chromatography (HPLC)-Based High-Resolution Anti-Proliferative Profile

Fractionation methods with traditional column chromatography cannot overcome the problem of overlapping secondary metabolites, which reduces the accuracy of the following bioassay-guided isolation step for the purification of pure compounds with biological activity. To overcome this problem, we used high-performance liquid chromatography (HPLC) to ensure the distinctive separation of the test fractions during bioassay. The chromatogram retention time (per 1 min)-based fractionation of an ethyl acetate (EtOAc) extract of Streptomyces sp. LY1209 was performed within 70 min. The collected fractions (at a concentration of 1 µg/mL) were further subjected to MTT cell proliferation assay to provide a high-resolution cell proliferative profile against Molt 4 cells (Figure 1). Among all test fractions, the 59th to 64th fractions (labeled with transparent red) exhibited the most potent activity. The corresponding tailing peak in the HPLC profile was identified as staurosporine (12) [16] using nuclear magnetic resonance (NMR) and mass (MS) spectroscopy. Other chromatographic peaks showing relatively less anti-proliferative activity, such as the 44th to 49th fractions (labeled with transparent blue), were also selected for scale-up production. Further separation and isolation were performed to yield eleven diketopiperazines (DKPs) (Figure 2), which were elucidated as 3-(4-hydroxybenzyl)-hexahydro-pyrido[1,2-al]pyrazine-1,4-dione (1), cyclo-(Ala-Phe) (2) [17], cyclo-(Gly-Phe) (3) [18], cyclo-(Pro-Tyr) (4) [19], cyclo-(Ala-Val) (5) [20], cyclo-(Ile-Ala) (6) [21], cyclo-(Leu-Ala) (7) [22], cyclo-(Gly-Leu) (8) [23], (3S,7R,8aS)-7-hydroxy-3-isopropylhexahydropyrrolo[1,2-al]pyrazine-1,4-dione (9) [24], cyclo(Leu-hydroxy-Pro) (10) [23], and 4-(2-aminoethyl)-phenylacetate (11) [25].
Figure 1. High-resolution anti-proliferative profile of the ethyl acetate (EtOAc) extract (1 μg/mL) of *Streptomyces* sp. LY1209 against Molt 4 cells.

Figure 2. The identified compounds (1–12) from EtOAc extract of *Streptomyces* sp. LY1209.
2.2. Structure Elucidation of Diketopiperazines (DKPs) Obtained from Streptomyces sp. LY1209

Compound 1 was obtained as a yellow amorphous solid. The molecular formula of 1 was revealed to be C_{15}H_{16}N_{2}O_{3} based on the HRESIMS peak at m/z 275.1406 (calculated for C_{15}H_{19}N_{2}O_{3}, 275.1396, and 13C NMD data suggesting eight degrees of unsaturation). The IR spectrum revealed the presence of hydroxyls, carbonyls, benzene rings, and NH-bonded moieties. Based on the 13C NMR (in CD_{3}OD) and DEPT spectroscopic data of 1 (Table 1), fifteen carbon signals were observed including five sp^3 methylene groups (δC 24.8, 25.3, 31.6, 40.9, and 43.3); two sp^3 methines (δC 57.2 and 58.4); four sp^2 olefinic methines (δC 116.2 (two overlapped signals) and 132.5 (two overlapped signals)); and four quaternary carbons (δC 126.5, 158.2, 167.0, and 169.9). Among these NMR signals, two amide carbonyls at δC 167.0 (C) and 169.9 (C) were characterized, along with C-3 (57.2) and C-6 (58.4), suggesting a diketopiperazine skeleton [26]. This functionality was also supported by the HMBC cross-peaks (Figure 3) from H-3 (δH 4.23) to C-2 (δC 167.0) and to C-5 (δC 169.9). A 1,4-disubstituted phenyl group was suggested based on a pair of overlapping signals at δH 6.70 (2H, d, 8.5 Hz)/δC 116.2 (CH) and 6.91 (2H, d, 8.5 Hz)/δC 132.5 (CH). The connection between both moieties was determined according to the HMBC correlations from H-11 (δH 3.17) to C-3 (δC 57.2) and C-12 (δC 126.5). Furthermore, the elucidated phenyl diketopiperazine group accounted for seven of the total eight degrees of unsaturation, implying the presence of an additional ring. The assignment of the additional piperidine group was elucidated based on the COSY (Figure 3) correlations of H-6/H-7, H-7/H-8, H-7/H-9, H-8/H-9, and H-9/H-10. Thus, the planar structure of 1 was verified.

Table 1. 1H (500 MHz, CD_{3}OD) and 13C (125 MHz, CD_{3}OD) NMR data for 1.

| Position | δH (J in Hz) a | δC (Mult.) b | 1H-1H COSY | HMBC |
|----------|----------------|--------------|-------------|------|
| 2        | 167.0 (C)      |              |             |      |
| 3        | 4.23, td (3.9, 1.3) c | 57.2 (CH) d | H-11       | C-2, C-5 |
| 5        | 169.9 (C)      |              |             |      |
| 6        | 2.54, dd (11.3, 1.6) | 58.4 (CH)    | H-7        |      |
| 7        | 1.32, m; 2.09, d (11.0) | 31.6 (CH_{2}) |             |      |
| 8        | 1.33, m; 1.83, m | 24.8 (CH_{2}) | H-7, H-9   |      |
| 9        | 1.33, m; 1.65, m | 25.3 (CH_{2}) | H-7, H-8, H-10 |      |
| 10       | 2.20, td (12.9, 3.2); 4.50, dt (13.5, 2.0) | 43.3 (CH_{2}) | H-8, H-9 |      |
| 11       | 3.17, dd (14, 1.8) | 40.9 (CH_{2}) | H-3        | C-2, C-3, C-12, C-13 |
|          | 126.5 (C)      |              |             |      |
| 12       | 126.5 (C)      |              |             |      |
| 13, 13’ | 6.91, d (8.5)u | 132.5 (CH)   | H-14       | C-11, C-15 |
| 14, 14’ | 6.70, d (8.5) | 116.2 (CH)   | H-13       | C-12, C-15 |
| 15       | 158.2 (C)      |              |             |      |

a 500 MHz in CDCl_{3}; b 125 MHz in CDCl_{3}; c J values (Hz) are given in parentheses; d Numbers of the attached protons were deduced by DEPT experiments.

Based on the 1H NMR coupling constants of this type of compound [27], the α-face-H-6 and trans-ring junction of 1 were suggested from the coupling constant of H-6 (11.3, 1.6 Hz). The NOESY correlations between H-6/H-7, H-6/H-10, H-7α/H-8α, H-9α/H-10α indicated the same orientation of these protons, referring to the 6S of 1. Additionally, the 3R configuration was elucidated based on the NOESY correlation of H-3/H-13, as well as the non-cross-peak between H-3 and H-6. Consequently, compound 1 was established and named as 3-(4-hydroxybenzyl)-hexahydro-pyrido[1,2-a]pyrazine-1,4)-dione.
Compounds 2–11 were identified by comparing their NMR data with those reported in previous literature (Figures S12–S46). The molecular weights of the identified compounds were also confirmed using MS spectrometry. Among these compounds, 9 and 10 were isolated from natural sources for the first time.

2.3. Anti-Proliferative Assessments of the Isolated Compounds

The biological activity of the isolated DKPs and the indolocarbazole against Molt 4 cell lines was evaluated using the MTT cell proliferation assay (Table 2). The results indicated the potent anti-proliferative activity of 12 (IC\textsubscript{50}: 0.01 \(\mu\)M). Among all the tested DKPs, only the derivative with 3-sec-butyl functionality exhibited moderate activity (IC\textsubscript{50}: 56.23 \(\mu\)M), suggesting the importance of this functionality for further medicinal modification. Therefore, staurosporine (12) was suggested to dominate the anti-proliferative activity of the EtOAc extract of Streptomyces sp. LY1209 against the Molt 4 cell.

Table 2. Anti-proliferative activity of the isolated metabolites from the ethyl EtOAc extract of Streptomyces sp. LY1209.

| Compounds | Cell Lines (IC\textsubscript{50} \(\mu\)M) |
|-----------|----------------------------------|
|           | Molt 4                           |
| 1         | 95.93 ± 2.32                     |
| 2         | _ \textsuperscript{a}           |
| 3         | _ \textsuperscript{a}           |
| 4         | _ \textsuperscript{a}           |
| 5         | _ \textsuperscript{a}           |
| 6         | 56.23 ± 7.52                     |
| 7         | _ \textsuperscript{a}           |
| 8         | _ \textsuperscript{a}           |
| 9         | _ \textsuperscript{a}           |
| 10        | _ \textsuperscript{a}           |
| 11        | _ \textsuperscript{a}           |
| 12        | 0.01 ± 0.001 \textsuperscript{b}|
| Doxorubicin \textsuperscript{b} | 0.04 |

\textsuperscript{a} IC\textsubscript{50} > 100 \(\mu\)M for 72 h; \textsuperscript{b} positive control.

2.4. Navigating Potential Therapeutical Targets of Anti-Proliferative Compounds Using ChemGPS-NP

Since the innovation of Lipinski’s rule-of-five, characterizing the drug-likeness of natural small molecules based on certain chemical and physical properties has become a promising approach for the development of potential lead compounds [28]. The recently developed principal component analysis (PCA)-based computational model, chemical global positioning system for natural products (ChemGPS-NP) [29], can assist in map-
ping the drug-likeness of compounds in virtual chemical space, and can further illustrate their potential pharmacological or biological targets [30–37]. ChemGPS-NP was applied to predict the possible therapeutic targets of our compounds compared with clinical chemotherapeutic agents with six prominent action modes, including alkylating agents, anti-metabolites, proteasome inhibitors, tyrosine kinase inhibitors, topoisomerase inhibitors, and anti-microtubule agents. The results (Figure 4) suggest that DKPs (labeled as black cubes) are potential anti-microtubule and alkylating agents, due to their similar location in the ChemGPS-NP chemical space with the corresponding clinical agents, while staurosporine was predicted to be a tyrosine kinase inhibitor.

![Figure 4. The plotted mode of action-relevant chemical patterns of the isolated compounds (DKPs 1–11 (black), and 12 (dark blue)), and the clinical chemotherapeutic agents searched from the ChEMBL database (alkylating agents (green, 19 compounds), anti-metabolites (orange, 21 compounds), proteasome inhibitors (yellow, 4 compounds), tyrosine kinase inhibitors (pink, 74 compounds), topoisomerase inhibitors (brown, 3 compounds), and anti-microtubule agents (light blue, 642 compounds)). The score plot was marked with three dimensions (principal components) including PC1 (red) describing the size, shape, and polarizability; PC2 (blue) representing the aromatic- and conjugation-related properties; and PC3 (yellow) depicting lipophilicity, polarity, and H-bond capacity. The overall view (A) and the individual views (B) of the analytical results.

The proposed mode of action of DKPs (1–11) was previously proven through the synthesis of DKPs with anti-microtubule [38,39] and alkylating [40,41] activities. The predicted mode of action of staurosporine (12) as a multi-targeted protein kinase inhibitor, is similar to that reported for a closely related derivative, midostaurin [42], suggesting the potential application of indolocarbazole derivatives for the treatment of ALL.

3. Materials and Methods

3.1. General Experimental Procedure

IR spectra were measured on a Fourier-transform IR spectrophotometer, Varian Digilab FTS 1000 (Varian Inc., Palo Alto, CA, USA). NMR spectroscopic analyses were performed using a Varian Unity INOVA 500 FT-NMR instrument (Varian Inc., Palo Alto, CA, USA). High-resolution electrospray ionization mass spectrometry (HRESIMS) analyses were carried out using a Bruker APEX II instrument (Bruker Daltonik, Bremen, Germany). All methods were carried out following the relevant guidelines and regulations.

3.2. Isolation, Culture, and Extraction of Marine Bacteria

Marine bacterium strain *Streptomyces* sp. LY1209 was isolated from benthic sediment, which was collected from the Kenting coast, south of Taiwan on 6 September 2012, at a depth of 2000 m. The bacterium strain LY1209 was 99% identical to *Streptomyces fradiae*
(Genebank accession no. NR043485.1) based on the 16S rRNA gene sequence. The marine bacterium was cultured in 2.5 L flasks containing 1 L M1 broth (1% starch, 0.4% yeast extract, 0.2% peptone, without agar) with 80% seawater. The bacterial culture was incubated at 25 °C in an orbital shaker (120 rpm). The incubation was terminated after five days by adding ethyl acetate (EtOAc, 3 × 60 L) to extract the culture broth (60 L). The total obtained extract was 6.64 g.

3.3. Fraction Preparation for HPLC-Based High-Resolution Anti-Proliferative Assay

A Hitachi Elite LaChrom HPLC system (Hitachi, Tokyo, Japan) consisting of a Hitachi L-2130 pump and a Hitachi L-2455 Photodiode Array Detector was employed to profile the EtOAc extract of *Streptomyces* sp. LY1209. Liquid chromatography was performed using a COSMOSIL 5C18-MS-II Waters (20 × 250 mm, C₁₈) column (Nacalai Tesque, Kyoto, Japan). The mobile phase was mixed with MeOH (M) and water (W). A gradient sequence was executed as follows: The initial eluting condition was M–W (10:90, v/v) at 25 min, M–W (45:55, v/v) at 30 min, then the final condition was M–W (80:20, v/v) at 70 min. The flow rate was set at 5 mL/min, the temperature of the column was maintained at 25 °C, and the detection wavelength was fixed at 220 nm. As for the dry EtOAc extract, 10 mg was dissolved in 100 µL of methanol and filtered through a 0.45 µm membrane filter before loading onto the HPLC column. Then, sample injection was performed manually with 100 µL volume per injection. Fractionation yielded a total of 70 fractions, which were collected every 1 min according to the retention time. The solvents of the collected fractions were removed using a sample concentrator and vacuum evaporator. At a concentration of 1 µg/mL, all fractions were subjected to the final MTT cell proliferation assay to examine their anti-proliferative properties. The fractions with anti-proliferative potential were produced in larger quantities and were subjected to reversed-phase chromatographic isolation and purification. The purification of DKPs (1–11) from the 44th to 49th fractions was executed by isocratic elution (M–W (50:50, v/v)). The combination of the 59th to 64th fractions, obtained by gradient elution, yielded pure staurosorone (12). The identification of the isolated compounds was completed based on a comparison between the obtained spectroscopic data (nuclear magnetic resonance (NMR) and mass (MS) spectra) and the previously reported ones (please refer to the spectroscopic data in the Supplementary Materials).

3-(4-Hydroxybenzyl)-hexahydro-pyrido[1,2-a]pyrazine-1,4-dione (1): Yellow powder; IR 3367, 1635 cm⁻¹; UV-vis (MeOH) λ_max (log ε) 206, 219, 239, 278, 289 nm; 1H (500 MHz, CD₃OD) and 1³C (125 MHz, CD₃OD) NMR spectroscopic data, Table 1; ESIMS m/z 481 [M + H]⁺; HRESIMS m/z 481.2925 [M + H]⁺ (calcd. for C₂₈H₄₂O₅, 481.29245).

Cyclo-(Ala-Phe) (2): White needles, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data; ESIMS m/z 219 [M + H]⁺.

Cyclo-(Gly-Phe) (3): White amorphous powder, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data, Table S2; ESIMS m/z 205 [M + H]⁺.

Cyclo-(Pro-Tyr) (4): Yellow oil, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data, Table S3; ESIMS m/z 261 [M + H]⁺.

Cyclo-(Ala-Val) (5): White powder, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data, Table S4; ESIMS m/z 171 [M + H]⁺.

Cyclo-(Ile-Ala) (6): White powder, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data, Table S5; ESIMS m/z 185 [M + H]⁺.

Cyclo-(Leu-Ala) (7): white amorphous, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data, Table S2; ESIMS m/z 185 [M + H]⁺.

Cyclo-(Gly-Leu) (8): White powder, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data, Table S7; ESIMS m/z 171 [M + H]⁺.

(3S,7R,8aS)-7-Hydroxy-3-isopropylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione (9): colorless oil, ¹H (500 MHz, CD₃OD) and ¹³C (125 MHz, CD₃OD) NMR spectroscopic data, Table S8; ESIMS m/z 213 [M + H]⁺.
Cyclo(Leu-hydroxy-Pro) (10): Colorless crystals, $^1$H (500 MHz, CD$_3$OD) and $^{13}$C (125 MHz, CD$_3$OD) NMR spectroscopic data, Table S9.

4-(2-Aminoethyl)-phenyl acetate (11): White powder, $^1$H (500 MHz, CD$_3$OD) and $^{13}$C (125 MHz, CD$_3$OD) NMR spectroscopic data, Table S10; ESIMS $m/z$ 180 [M + H]$^+$. 

Staurosporine (12): Amorphous powder, $^1$H (400 MHz, CDCl$_3$): 9.41 (1H, d, $J$ = 7.6 Hz, H-4), 7.92 (1H, d, $J$ = 8.4 Hz, H-11), 7.88 (1H, d, $J$ = 7.6 Hz, H-8), 7.48 (1H, t, $J$ = 8.0 Hz, H-2), 7.42 (1H, t, $J$ = 8.0 Hz, H-10), 7.36 (1H, d, $J$ = 8.0 Hz, H-3), 7.31 (1H, t, $J$ = 8.0 Hz, H-9), 7.28 (1H, t, $J$ = 8.0 Hz, H-1), 6.55 (1H, d, $J$ = 5.2 Hz, H-6$'$), 5.01 (2H, s, H-7), 3.87 (1H, d, $J$ = 3.2 Hz, H-3$'$), 3.40 (3H, s, H-3$'$-OMe), 3.34 (1H, q, $J$ = 3.6 Hz, H-4$'$), 2.74 (1H, dd, $J$ = 14.8, 3.2 Hz, H-5$'$), 2.39 (1H, ddd, $J$ = 14.4, 6.0, 3.6 Hz, H-5$'$), 2.35 (3H, s, H-2$'$-OMe), 1.55 (3H, s, H-4$'$-NMe).

3.4. MTT Proliferation Assay

MTT assay was used to assess the proliferation of Molt-4 (human T lymphoblast, acute lymphoblastic leukemia) cells after treatment with all fractions and compounds. The Molt 4 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Culture plates with 96 wells were used for the MTT assay. For the anti-proliferative assessments in Figure 1, Molt-4 cells were seeded at $2 \times 10^5$ per well and were treated with 1 µg/mL of all fractions. For the evaluations in Table 2, Molt-4 cells were seeded at $2 \times 10^5$ per well and were treated with 100, 50, 25, and 12.5 µM of the tested DKPs (1–11); with 10, 1, 0.1, 0.01, and 0.001 µM of the compound 12 and positive control (Doxorubicin). The anti-proliferative effect of the test fractions and compounds was determined by MTT cell proliferation assay (thiazolyl blue tetrazolium bromide, Sigma-M2128) for 24, 48, or 72 h. An ELISA reader (Anthoslabtec Instrument, Salzburg, Austria) was used to measure light absorbance values (OD = OD$_{570}$ − OD$_{620}$) at 570 and 620 nm. Calculations were performed to determine the concentration that led to 50% inhibition (IC$_{50}$). The results were expressed as a percentage of the control ± SD established from $n = 3$ wells per experiment, from three independent experiments.

3.5. ChemGPS-NP Analysis

The game global positioning system is a public tool for navigation in biologically relevant chemical space. It has eight principal components (PCs) based on 35 carefully selected chemical descriptors describing physical–chemical properties, including size, shape, polarizability, lipophilicity, polarity, and hydrogen bond capacity. The ChemGPS-NP score predictions were calculated through an online tool, ChemGPS-NPWeb (http://chemgps.bmc.uu.se (accessed on 2 November 2021)) based on their structural information as a simplified molecular input line entry specification (SMILES), derived via ChemBioDraw version 16.0 (CambridgeSoft, Waltham, MA, USA). The involvements of chemotherapeutic agents were categorized according to the ChEMBL database using keywords of alkylating agents, anti-metabolites, proteasome inhibitors, tyrosine kinase inhibitors, topoisomerase, and anti-microtubule agents, and were plotted into the ChemGPS-NP chemical space using the software Grapher 2.6 (Mac OS, Cupertino, CA, USA).

4. Conclusions

We identified anti-leukemic metabolites from marine-derived Streptomyces sp. LY1209 and determined their possible molecular targets. A series of diketopiperazines (DKPs) were identified including one novel (1) and two known compounds (9 and 10) isolated for the first time from natural resources. An indolocarbazole derivative exhibited the most potent anti-proliferative activity. A chemo-informatic approach, ChemGPS-NP analysis, illustrated the possible molecular targets of these bioactive metabolites. The strategy developed in this study can be employed to facilitate the future discovery of potential anti-leukemic drug leads.
Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/metabo12040320/s1, Table S1: 1D and 2D NMR (600 MHz, CD3OD) data of 1, Table S2: 1D NMR (500 MHz, CD3OD) data of 2, Table S3: 1D NMR (500 MHz, CD3OD) data of 3, Table S4: 1D (500 MHz, CD3OD) data of 4, Table S5: 1D NMR (500 MHz, CD3OD) data of 5, Table S6: 1D (500 MHz, CD3OD) data of 6, Table S7: 1D NMR (500 MHz, CD3OD) data of 7, Table S8: 1D NMR (500 MHz, CD3OD) data of 8, Table S9: 1D NMR (500 MHz, CD3OD) data of 9, Table S10: 1D NMR (500 MHz, CD3OD) data of 10, Table S11: 1D NMR (500 MHz, CD3OD) data of 11; Figure S1: IR spectrum of 1, Figure S2: UV-VIS spectrum of 1, Figure S3: HREMS spectrum of 1, Figure S4: 1H NMR (500 MHz, CD3OD) spectrum of 1, Figure S5: 1H NMR (500 MHz, CD3OD) spectrum of 1 (Partial enlarged view), Figure S6: 13C NMR (125 MHz, CD3OD) spectrum of 1, Figure S7: DEPT spectrum of 1, Figure S8: HSQC spectrum of 1, Figure S9: HMBC spectrum of 1, Figure S10: COSY spectrum of 1, Figure S11: NOESY spectrum of 1, Figure S12: ESIMS spectrum of 2, Figure S13: 1H NMR (500 MHz, CD3OD) spectrum of 2, Figure S14: 13C NMR (125 MHz, CD3OD) spectrum of 2, Figure S15: DEPT spectrum of 2, Figure S16: ESIMS spectrum of 3, Figure S17: 1H NMR (500 MHz, CD3OD) spectrum of 3, Figure S18: ESIMS spectrum of 4, Figure S19: 1H NMR (500 MHz, CD3OD) spectrum of 4, Figure S20: 13C NMR (125 MHz, CD3OD) spectrum of 4, Figure S21: DEPT spectrum of 4, Figure S22: ESIMS spectrum of 5, Figure S23: 1H NMR (500 MHz, CD3OD) spectrum of 5, Figure S24: 13C NMR (125 MHz, CD3OD) spectrum of 5, Figure S25: DEPT spectrum of 5, Figure S26: ESIMS spectrum of 6, Figure S27: 1H NMR (500 MHz, CD3OD) spectrum of 6, Figure S28: 13C NMR (125 MHz, CD3OD) spectrum of 6, Figure S29: DEPT spectrum of 6, Figure S30: ESIMS spectrum of 7, Figure S31: 1H NMR (500 MHz, CD3OD) spectrum of 7, Figure S32: 13C NMR (125 MHz, CD3OD) spectrum of 7, Figure S33: DEPT spectrum of 7, Figure S34: ESIMS spectrum of 8, Figure S35: 1H NMR (500 MHz, CD3OD) spectrum of 8, Figure S36: 13C NMR (125 MHz, CD3OD) spectrum of 8, Figure S37: DEPT spectrum of 8, Figure S38: ESIMS spectrum of 9, Figure S39: 1H NMR (500 MHz, CD3OD) spectrum of 9, Figure S40: 13C NMR (125 MHz, CD3OD) spectrum of 9, Figure S41: DEPT spectrum of 9, Figure S42: 1H NMR (500 MHz, CD3OD) spectrum of 10, Figure S43: 13C NMR (125 MHz, CD3OD) spectrum of 10, Figure S44: DEPT spectrum of 10, Figure S45: ESIMS spectrum of 11, Figure S46: 1H NMR (500 MHz, CD3OD) spectrum of 11, Figure S47: 13C NMR (125 MHz, CD3OD) spectrum of 11, Figure S48: DEPT spectrum of 11.

Author Contributions: K.-H.L., L.-S.W. and P.-J.C. conceived and designed the experiments; Y.-Y.C., K.-H.L., L.-S.W. and P.-J.C. contributed the reagents and analytical tools; L.-Y.C., B.-R.P., Y.-C.C., J.-H.S. and P.-J.C. participated in data interpretation, wrote the manuscript and revised the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a grant from the Ministry of Science and Technology, Taiwan (MOST 110-2320-B-038-034 and MOST 109-2320-B-650-001-MY3); Ministry of Education, Taiwan (DP2-110-21121-01-N-12-03); and from Taipei Medical University (TMU109-AE1-B15).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the article and Supplementary Materials.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. PDQ Adult Treatment Editorial Board. Adult Acute Lymphoblastic Leukemia Treatment (PDQ(R)): Health Professional Version; PDQ Cancer Information Summaries; National Cancer Institute: Bethesda, MD, USA, 2002.
2. Jabbour, E.; Thomas, D.; Cortes, J.; Kantarjian, H.M.; O’Brien, S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: Current and emerging therapies. Cancer 2010, 116, 2290–2300. [CrossRef] [PubMed]
3. Kraszewska, M.D.; Dawidowska, M.; Szczepanski, T; Witt, M. T-cell acute lymphoblastic leukaemia: Recent molecular biology findings. Br. J. Haematol. 2012, 156, 303–315. [CrossRef] [PubMed]
4. Durinck, K.; Goossens, S.; Peirs, S.; Wallaert, A.; Van Loocke, W.; Matthijssens, F.; Pieters, T.; Milani, G.; Lammens, T.; Rondou, P.; et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp. Hematol. 2015, 43, 625–639. [CrossRef] [PubMed]
1. Kuehl, F.A., Jr.; Peck, R.L.; Walti, A.; Folkers, K. Streptomycytes antibiotics I crystalline salts of streptomycin and streptothricin. *Science* **1945**, *102*, 34–35. [CrossRef] [PubMed]

2. Alshaibani, M.M.; Mohammad Zin, N.; Jallil, J.; Sidik, N.M.; Ahmad, S.J.; Kamal, N.; Edrada-Ebel, R. Isolation, purification, and characterization of five active diketopiperazine derivatives from endophytic *Streptomyces* SUK 25 with antimicrobial and cytotoxic activities. *J. Microbiol. Biotechnol.* **2017**, *27*, 2074. [CrossRef]

3. Nishanth Kumar, S.; Mohandas, C.; Siji, J.V.; Rajasekharan, K.N.; Nambisan, B. Identification of antimicrobial compound, diketopiperazines, from a *Bacillus* sp. *N* strain associated with a rhizobitid entomopathogenic nematode against major plant pathogenic fungi. *J. Appl. Microbiol.* **2012**, *113*, 914–924. [CrossRef]

4. Kohn, H.; Widger, W. The molecular basis for the mode of action of bicyclomycin. *Curr. Drug Targets Infect. Disord.* **2005**, *5*, 273–295. [CrossRef]

5. Kouchaksaraee, R.M.; Li, F.; Nazemi, M.; Farimani, M.M.; Thademir, D. Molecular networking-guided isolation of new etionine-type diketopiperazine hydroxamates from the persian gulf sponge *Cliona celata*. *Mar. Drugs* **2021**, *19*, 439. [CrossRef]

6. Lucietto, F.R.; Milne, P.J.; Kilian, G.; Frost, C.L.; Van De Venter, M. The biological activity of the histidine-containing diketopiperazines cyclo(His-Ala) and cyclo(His-Gly). *Peptides* **2006**, *27*, 2706–2714. [CrossRef]

7. Steilmasiewicz, M.; Swiatek, L.; Ludiwiczuk, A. Phytochemical profile and anticancer potential of endophytic microorganisms from liverwort species, *Marchantia polymorpha* *L*. *Molecules* **2021**, *27*, 153. [CrossRef]

8. Tangerina, M.M.P.; Furtado, L.C.; Leite, V.M.B.; Bauermeister, A.; Velasco-Alzate, K.; Jimenez, P.C.; Garrido, L.M.; Padilla, G.; Lopes, N.P.; Costa-Lotufo, L.V.; et al. Metabolomic study of marine *Streptomyces* sp.: Secondary metabolites and the production of potential anticancer compounds. *PLoS ONE* **2020**, *15*, e0244385. [CrossRef] [PubMed]

9. Jinendiran, S.; Teng, W.; Dahms, H.U.; Liu, W.; Ponnamusamy, V.K.; Chiu, C.C.; Kumar, B.S.D.; Sivakumar, N. Induction of mitochondrial-mediated apoptosis and suppression of tumor growth in zebrafish xenograft model by cyclic dipeptides identified from *Exiguobacterium acetylicum*. *Sci. Rep.* **2020**, *10*, 13721. [CrossRef] [PubMed]

10. Garrido Gonzalez, F.P.; Mancilla Percino, T. Synthesis, docking study and inhibitory activity of 2,6-diketopiperazines derived from alpha-amino acids on HDAC8. *Bioorg. Chem.* **2020**, *102*, 104080. [CrossRef] [PubMed]

11. Rhee, K.H. Isolation and characterization of *Streptomyces* sp. KH-614 producing anti-VRE (vancomycin-resistant enterococci) antibiotics. *J. Gen. Appl. Microbiol.* **2002**, *48*, 321–327. [CrossRef]

12. Schupp, P.; Eder, C.; Proksch, P.; Wray, V.V.; Schneider, B.; Herderich, M.; Paul, V.V. Stauroporine derivatives from the ascidian eudistoma toaleonis and its predatory flatworm *Pseudoceros* sp. *J. Nat. Prod.* **1999**, *62*, 959–962. [CrossRef] [PubMed]

13. Jiang, Q.; Wei, N.; Huy, G.; Xang, G.; Chen, G.; Wen, L. Secondary metabolites of the endophytic fungus *Cladosporium* sp. *Cytotoxic Chem. Nat. Compd.* **2020**, *56*, 1166–1169. [CrossRef]

14. Lu, X.; Chen, Y.; Zhu, Y.; Xu, Q.; Liu, X.; Ni, K.; Cao, X.; Zhang, W.; Jiao, B. An endophytic actinomycete from marine bacteria *Bacillus subtilis*. *Chem. Nat. Compd.* **2009**, *45*, 290–292. [CrossRef]

15. Nalli, Y.; Gupta, S.; Khajuria, V.; Singh, V.P.; Saigotra, M.; Ahmed, Z.; Thakur, N.L.; Ali, A. TNF-α and IL-6 inhibitory effects of cyclic dipeptides isolated from marine bacteria *Streptomyces* sp. *Med. Chem. Res.* **2016**, *25*, 93–100. [CrossRef]

16. Zhao, J.Y.; Ding, J.H.; Li, Z.H.; Feng, T.; Zhang, H.B.; Liu, J.K. A new cyclic dipeptide from cultures of *Coprinus plicatilis*. *Nat. Prod. Res.* **2018**, *32*, 972–976. [CrossRef]

17. Chen, L.; Guo, Q.-f.; Ma, J.-w.; Kang, W.-y. Characterization of several *Streptomyces* bacteria LL1103. *Chem. Nat. Compd.* **2018**, *54*, 419–420. [CrossRef]

18. Tian, S.; Yang, Y.; Liu, K.; Xiong, Z.; Xu, L.; Zhao, L. Antimicrobial metabolites from a novel halophilic actinomycete *Nocardiopsis terrae* YM 90022. *Nat. Prod. Res.* **2014**, *28*, 344–346. [CrossRef]

19. Wei, J.; Zhang, X.Y.; Deng, S.; Cao, L.; Xue, Q.H.; Gao, J.M. Alpha-glucosidase inhibitors and phytotoxins from *Streptomyces xanthophaeus*. *Nat. Prod. Res.* **2017**, *31*, 2062–2066. [CrossRef] [PubMed]

20. Harish, V.; Periasamy, M. Enantiomerically pure piperazines via NaBH4/I2 reduction of cyclic amidines. *Tetrahedron* **2017**, *73*, 175–180. [CrossRef]

21. Wild, G.P.; Wiles, C.; Watts, P.; Haswell, S.J. The use of immobilized crown ethers as in-situ N-protecting groups in organic synthesis and their application under continuous flow. *Tetrahedron* **2009**, *65*, 1618–1629. [CrossRef]

22. Noel, A.; Ferron, S.; Rouaud, I.; Gouault, N.; Hurvois, J.P.; Tomasi, S. Isolation and structure characterization of five active diketopiperazine derivatives from *Streptomyces* sp.: Secondary metabolites and the production of potential anticancer compounds. *Bull. Soc. Chim. Belg.* **2017**, *126*, 419–426. [CrossRef]

23. Schroten, R.; Joshi, S.; Anteusinis, M.J.O. A comparative study of the aggregation, rotational side-chain isomerism and side-chain/side-chain interactions in the cyclic dipeptides c/Phe, Pip/and c/Phe, (s)Pip. *Bull. Soc. Chim. Belg.* **2010**, *89*, 615–628. [CrossRef]

24. Benet, L.Z.; Hosey, C.M.; Ursu, O.; Oprea, T.I. BDDCS, the Rule of 5 and drugability. *Adv. Drug Deliv. Rev.* **2016**, *101*, 89–98. [CrossRef] [PubMed]

25. Rosen, J.; Lovgren, A.; Kogej, T.; Muresan, S.; Gottfries, J.; Backlund, A. ChemGPS-NP(Web): Chemical space navigation online. *J. Comput. Aided Mol. Des.* **2009**, *23*, 253–259. [CrossRef] [PubMed]

26. Lai, K.H.; Lu, M.C.; Du, Y.C.; El-Shazly, M.; Wu, T.Y.; Hsu, Y.M.; Henz, A.; Yang, J.C.; Backlund, A.; Chang, F.R.; et al. Cytotoxic lanostanoids from *Porzia cocos*. *J. Nat. Prod.* **2016**, *79*, 2705–2813. [CrossRef]

27. Korinek, M.; Tsai, Y.H.; El-Shazly, M.; Lai, K.H.; Backlund, A.; Wu, S.F.; Lai, W.C.; Wu, T.Y.; Chen, S.L.; Wu, Y.C.; et al. Anti-allergic hydroxy fatty acids from *Typhonium blumei* explored through ChemGPS-NP. *Front. Pharmacol.* **2017**, *8*, 356. [CrossRef] [PubMed]
32. Yang, L.; Chai, C.Z.; Yan, Y.; Duan, Y.D.; Henz, A.; Zhang, B.L.; Backlund, A.; Yu, B.Y. Spasmolytic mechanism of aqueous licorice extract on oxytocin-induced uterine contraction through inhibiting the phosphorylation of heat shock protein 27. *Molecules* 2017, 22, 1392. [CrossRef] [PubMed]

33. Xu, J.H.; Lai, K.H.; Su, Y.D.; Chang, Y.C.; Peng, B.R.; Backlund, A.; Wen, Z.H.; Sung, P.J. Briaviolides K-N, new briarane-type diterpenoids from cultured octocoral *Briareum violaceum*. *Mar. Drugs* 2018, 16, 75. [CrossRef] [PubMed]

34. Henz Ryen, A.; Backlund, A. Charting angiosperm chemistry: Evolutionary perspective on specialized metabolites reflected in chemical property space. *J. Nat. Prod.* 2019, 82, 798–812. [CrossRef] [PubMed]

35. Alajlani, M.M.; Backlund, A. Evaluating antimycobacterial screening schemes using chemical global positioning system-natural product analysis. *Molecules* 2020, 25, 945. [CrossRef] [PubMed]

36. Lai, K.H.; Peng, B.R.; Su, C.H.; El-Shazly, M.; Sun, Y.L.; Shih, M.C.; Huang, Y.T.; Yen, P.T.; Wang, L.S.; Su, J.H. Anti-proliferative potential of secondary metabolites from the marine sponge *Theonella* sp.: Moving from correlation toward causation. *Metabolites* 2021, 11, 532. [CrossRef]

37. Alajlani, M.M. The chemical property position of bedaquiline construed by a chemical global positioning system-natural product. *Molecules* 2022, 27, 753. [CrossRef] [PubMed]

38. Ding, Z.; Ma, M.; Zhong, C.; Wang, S.; Fu, Z.; Hou, Y.; Liu, Y.; Zhong, L.; Chu, Y.; Li, F.; et al. Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure. *Bioorg. Med. Chem.* 2020, 28, 115186. [CrossRef]

39. Hoffman, R.M.; Okuyama, K.; Kaida, A.; Hayashi, Y.; Hayashi, Y.; Harada, K.; Miura, M. KPU-300, a novel benzophenone-diketopiperazine-type anti-microtubule agent with a 2-pyridyl structure, is a potent radiosensitizer that synchronizes the cell cycle in early M phase. *PLoS ONE* 2015, 10, e0145995. [CrossRef] [PubMed]

40. Tullberg, M.; Grothli, M.; Luthman, K. Synthesis of functionalized, unsymmetrical 1,3,4,6-tetrasubstituted 2,5-diketopiperazines. *J. Org. Chem.* 2006, 72, 195–199. [CrossRef] [PubMed]

41. Vale, N.; Ferreira, A.; Matos, J.; Fresco, P.; Gouveia, M. Amino acids in the development of prodrugs. *Molecules* 2018, 23, 2318. [CrossRef]

42. Wu, M.; Li, C.; Zhu, X. FLT3 inhibitors in acute myeloid leukemia. *J. Hematol. Oncol.* 2018, 11, 133. [CrossRef] [PubMed]